Rationally designed hydrolytically activated etoposide prodrugs, a novel strategy for the treatment of neuroblastoma

Cancer Letters

Volumn 197, Issue 1-2, 2003, Pages 225-230

  Lange, B ^a   Schroeder, U ^a   Huebener, N ^a   Jikai, J ^a   Wenkel, J ^a   Strandsby, A ^a   Wrasidlo, W ^a   Gaedicke, G ^a   Lode, H N ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Chemotherapy; Cytotoxicity; Drug resistance; Etoposide; MDR 1; Neuroblastoma; Prodrugs; Xenograft

Indexed keywords

CARBONIC ACID; ETOPOSIDE; PRODRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER CHEMOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; FEMALE; HYDROLYSIS; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL LINE;

TRIXIS;

EID: 0038105281     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(03)00106-X     Document Type: Conference Paper

References (13)

1. Zhu B.T., novel A. hypothesis for the mechanism of action of P-glycoprotein as a multidrug transporter. Mol. Carcinog. 25:1999;1-13.
2. Chan H.S., Haddad G., Thorne P.S., DeBoer G., Lin Y.P., Ondrusek N., Yeger H., Ling V. P-Glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N. Engl. J. Med. 23:1991;1608-1614.
3. Dalton W.S. Mechanisms of drug resistance in hematologic malignancies. Semin. Hematol. 34:1997;3-8.
4. Kurowski C., Berthold F. Presence of classical multidrug resistance and P-glycoprotein expression in human neuroblastoma cells. Ann. Oncol. 9:1998;1009-1014.
5. Cowie F.J., Pritchard-Jones K., Renshaw J., Pinkerton C.R. Multidrug resistance modulation in rhabdomyosarcoma and neuroblastoma cell lines. Int. J. Oncol. 5:1998;1143-1149.
6. Sonneveld P., Durie B.G., Lokhorst H.M., Marie J.P., Solbu G., Suciu S., Zittoun R., Lowenberg B., Nooter K. Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON. Lancet. 340:1992;255-259.
7. Hunault M., Zhou D., Delmer A., Ramond S., Viguie F., Cadiou M., Perrot J.Y., Levy V., Rio B., Cymbalista F., Zittoun R., Marie J.P. Multidrug resistance gene expression in acute myeloid leukemia: major prognosis significance for in vivo drug resistance to induction treatment. Ann. Hematol. 74:1997;65-71.
8. Marie J.P., Zhou D.C., Gurbuxani S., Legrand O., Zittoun R. MDR1/P-glycoprotein in haematological neoplasms. Eur. J. Cancer 32A. 1996;1034-1038.
9. Wrasidlo W., Schroder U., Bernt K., Hubener N., Shabat D., Gaedicke G., Lode H. Synthesis, hydrolytic activation and cytotoxicity of etoposide prodrugs. Bioorg. Med. Chem. Lett. 4:2002;557-560.
10. Lode H.N., Xiang R., Varki N.M., Dolman C.S., Gillies S.D., Reisfeld R.A. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. J. Natl. Cancer Inst. 89:1997;1586-1594.
11. Legrand O., Perrot J.Y., Simonin G., Baudard M., Marie J.P. JC-1: a very sensitive fluorescent probe to test Pgp activity in adult acute myeloid leukemia. Blood. 97:2001;502-508.
12. Scudiero D.A., Shoemaker R.H., Paull K.D., Monks A., Tierney S., Nofziger T.H., Currens M.J., Seniff D., Boyd M.R. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res. 48:1988;4827-4833.
13. U. Schroeder, K.M. Bernt, B. Lange, Hydrolytically activated etoposide prodrug overcomes established MDR-1 multidrug resistant T-cell leukemia, Blood 2003 (in press).